Clinical Trial Update: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update evaluating tamoxifen citrate, letrozole, anastrozole, or exemestane with or without chemotherapy in invasive RxPONDER br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ
• Invasive Breast Cancer
• Multicentric Breast Cancer
• Multifocal Breast Cancer
• Synchronous Bilateral Breast Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Exemestane (Exemestane)
• Letrozole (letrozole)
• Tamoxifen citrate (tamoxifen citrate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-06-27